Association Between Genetic Polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT Genes and Radiosensitivity in Breast Cancer Patients

Predictive Value of Xrcc1 Gene Polymorphisms for Side Effects in Patients undergoing Whole Breast Radiotherapy: a Meta-analysis

“…The development of acute side effects of grade ≥2c according to the Common Toxicity Criteria of the U.S. NIH or ≥2 according to the CTCAE v3.0 or RTOG was considered to indicate increased sensitivity for acute effects in our study (Chang-Claude et al, 2005;Zhou et al, 2010;Mangoni et al, 2011;Raabe et al, 2012;Terrazzino et al, 2012). The development of late effects of grade ≥2 according to the CTCAE v3.0 or SOMA was considered to indicate increased sensitivity for late effects in our study (Giotopoulos et al, 2007;Chang-Claude et al, 2009;Zschenker et al, 2010;Falvo et al, 2012).…”

“…In a study by Moullan et al (Moullan et al, 2003), the 194Trp allele of the XRCC1 Arg194Trp polymorphism was found to be significantly associated with the risk of developing an adverse response to radiotherapy when analyzed in combination with the 399Gln allele of the XRCC1 Arg399Gln polymorphism. On the other hand, Mongani et al (Mangoni et al, 2011) showed that women carrying the combination of the XRCC1-194Trp and the XRCC1-399 Arg alleles were more likely to experience grade 2c or higher toxicity. The original data on such combination studies currently available are not sufficient for inclusion into a meta-analysis, suggesting that more emphasis should be placed on combination or haplotype analysis in future studies.…”

“…After application of critical search strategies and exclusion criteria, 11 follow-up studies (Moullan et al, 2003;Chang-Claude et al, 2005;Brem et al, 2006;Giotopoulos et al, 2007;Chang-Claude et al, 2009;Zhou et al, 2010;Zschenker et al, 2010;Mangoni et al, 2011;Falvo et al, 2012;Raabe et al, 2012;Terrazzino et al, 2012) comprising 2199 cases were eligible for the present analysis. The baseline characteristics of the included studies are shown in Table 1.…”

“…Data concerning the predictive value of the XRCC1 Arg399Gln allele with respect to the risk of radiationinduced toxicity in breast cancer patients were available in 10 trials comprising 1929 individuals (Moullan et al, 2003;Chang-Claude et al, 2005;Giotopoulos et al, 2007;Chang-Claude et al, 2009;Zschenker et al, 2010;Zhou et al, 2010;Mangoni et al, 2011;Terrazzino et al, 2012;Falvo et al, 2012;Raabe et al, 2012). No significant association between the 399Gln allele and radiationinduced toxicity was detected in the overall analysis (Table 3).…”

Biochemical markers predicting response to radiation- and radiochemo-therapy in cancer patients

“…2) данные немецких исследователей о повышении экспрессии ингибитора апоптоза -сурвивина, как маркера высокой опасности рецидивирования больных раком мочевого пузыря (РМП) [60,61], а также 3) данные итальянских специалистов о генетическом полиморфизме ряда ДНК-репарационных генов как предиктивном показателе радиочувствительности у больных РМЖ [74].…”